In one paragraphArticle in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors.
Cecilia Bivik EdingIngrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.ORCID 0000-0003-2769-0016 Ines KöhlerIngrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.ORCID 0000-0002-9260-8528 Lavanya MoparthiIngrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.ORCID 0000-0002-6030-3084 Florence SjögrenIngrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.
Blanka AnderssonIngrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.ORCID 0000-0002-9562-0872 Debojyoti DasIngrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.ORCID 0000-0001-6811-3333 Deepti VermaIngrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.
Martin ScobieOxcia AB, 113 34 Stockholm, Sweden.
Ulrika Warpman BerglundOxcia AB, 113 34 Stockholm, Sweden.
Charlotta EnerbäckIngrid Asp Psoriasis Research Center, Department of Biomedical and Clinical Sciences, Linköping University, 581 85 Linköping, Sweden.ORCID 0000-0003-1769-3790 Funding
ALF Grants, Region Östergötland n/aIngrid Asp Foundation n/athe Swedish Psoriasis Association n/athe Welander Foundation n/a
6 · The paper itselfAbstract
Topically applied TH1579 alleviated the psoriatic phenotype in the imiquimod-induced psoriasis mouse model by decreasing CD45
Indexed as
DNA Repair EnzymesPhosphoric Monoester HydrolasesPsoriasisS-Phase Kinase-Associated ProteinsWnt-5a ProteinAdministration, TopicalAnimalsCell ProliferationDisease Models, AnimalHumansImiquimodKeratinocytesMiceSkinDNA Repair EnzymesImiquimodPhosphoric Monoester HydrolasesS-Phase Kinase-Associated ProteinsWnt-5a ProteinWnt5a protein, mouseinflammationkeratinocytesMTH1proliferationpsoriasisskin
Identifiers
PMID40806307
PMCPMC12346197
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390